The North America CRISPR market is witnessing significant momentum, driven by advances in gene editing technologies, strategic collaborations, and increased funding. With expanding applications across therapeutics, agriculture, and diagnostics, the market is well-positioned for robust growth in the foreseeable future.
The economic impact of tariffs on "North America CRISPR Market".
Market Growth Drivers
Strategic Collaborations and Funding: Leading companies such as CRISPR Therapeutics and Editas Medicine have entered multiple partnerships to expand their research and clinical pipelines. Recent collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics for the development of gene-edited therapies has resulted in milestone achievements and additional financial backing. This influx of investment is accelerating development and commercialization of CRISPR-based solutions, propelling market growth.
Rising Prevalence of Genetic Disorders: There is an increasing demand for advanced genetic solutions due to the rising incidence of genetic disorders in North America. Companies like Intellia Therapeutics are focusing on harnessing CRISPR gene-editing technology to develop treatments for rare diseases, positioning the market at the forefront of medical innovation. Patient advocacy, combined with regulatory support, is stimulating adoption of such therapies at a faster pace.
Market Trends
Expansion Into Non-Therapeutic Sectors: CRISPR technology is increasingly being applied in agriculture and food, enabling improved crop varieties, pest resistance, and higher yield. Firms like Corteva Agriscience are spearheading advancements in gene-edited crops in the U.S., reflecting a broader trend of diversified application beyond therapeutics.
Automation and High-Throughput Screening: Technological innovations such as automation and high-throughput CRISPR screening platforms are enhancing research productivity. Companies like Synthego are investing heavily in automation tech, providing researchers with scalable gene editing solutions, reducing costs, and enabling faster turnaround times for a variety of genome engineering applications.
Market Opportunities
Emergence of In Vivo CRISPR Therapies: The success of first-in-human in vivo CRISPR trials presents a significant opportunity for companies like Editas Medicine to broaden their clinical portfolios and offer potentially curative treatments for previously intractable conditions.
Growth in Personalized Medicine: The integration of CRISPR into personalized medicine workflows is opening avenues for precision diagnostics and tailored therapies. This enables companies such as Beam Therapeutics to capture new market segments and develop unique, individualized treatment regimens.
North America CRISPR Market Revenue (USD Million), 2020-2035
The chart shows a strong growth trajectory for the North America CRISPR market, beginning at $430 million in 2020 and steadily increasing to reach $2,900 million by 2035. The most significant acceleration is projected to occur post-2027 as gene-edited therapies gain regulatory approvals and adoption in healthcare and agriculture surges. A compound annual growth rate (CAGR) of approximately 15.2% is observed during this period, underscoring high investor confidence and robust expansion opportunities across sectors.
North America CRISPR Market by Region, 2025
In 2025, the U.S. dominates the North America CRISPR market, accounting for 72% of the total market, driven by advanced research infrastructure, funding, and the presence of key players. Canada follows with a market share of 18%, reflecting growing investments and favorable regulatory support. Mexico holds an 8% share, with the remaining 2% attributed to other regions within North America. This distribution highlights market concentration in the U.S., although other regions are expected to grow faster as regulatory landscapes evolve.
Recent Developments in North America CRISPR Market (Last 6 Months)
In April 2024, CRISPR Therapeutics and Vertex Pharmaceuticals announced FDA approval of their CRISPR-based gene therapy for sickle cell disease (exa-cel), marking the first in vivo CRISPR treatment to receive market authorization in North America. This approval is expected to open doors for similar gene-edited therapies and accelerate clinical adoption.
In May 2024, Editas Medicine initiated the phase 2 clinical trial of its next-generation CRISPR-based gene editing therapy for inherited retinal diseases. The company's expansion into ocular therapies is regarded as a milestone, signaling further diversification of CRISPR's applications beyond hematological and oncological disorders.
In February 2024, Synthego announced a collaboration with Thermo Fisher Scientific to provide CRISPR research solutions for academic and pharmaceutical customers. The partnership aims to leverage Synthego’s automation technology and Thermo Fisher’s global reach, driving the commercialization of advanced CRISPR editing platforms.
Press Releases